WASHINGTON — Federal drug regulators announced plans Wednesday to convene a summer panel that will examine whether to relax current restrictions on seven peptide treatments that have gained popularity among fitness enthusiasts, wellness advocates and celebrity users.
The scheduled review comes after Health Secretary Robert F. Kennedy Jr. has repeatedly promised to reduce regulatory barriers for peptides, which promoters claim can rapidly increase muscle mass, accelerate injury recovery and provide anti-aging benefits. Scientific evidence supporting these assertions remains limited, and federal safety evaluations for most peptides are incomplete.
Kennedy has openly discussed his personal peptide use for treating injuries. Key figures in his Make America Healthy Again initiative also champion these treatments, including Gary Brecka, who markets himself as a “longevity expert” and sells peptide products online.
Federal regulators stated in Wednesday’s announcement that external pharmacy consultants will examine seven specific peptides during a July session, determining whether these substances should be removed from a restrictive category designated for high-risk, customized medications.
The review will include widely-promoted peptides like BPC-157, which vendors market for injury healing and inflammation reduction.
During the previous administration under President Joe Biden, federal officials placed over a dozen popular peptides on a prohibited list for compounding pharmacies — specialized businesses that create custom medications unavailable from traditional manufacturers.
When this restriction was implemented, FDA advisory panel members voted decisively that these peptides failed to qualify for the approved compounding list. Agency officials supported this determination, later stating the substances “present significant safety risks” due to insufficient human testing.
Most FDA advisers and staff members involved in those earlier decisions have since left the agency.
July’s panel will evaluate whether BPC-157, TB-500 and five additional peptides merit inclusion on the approved compounding list. The federal notice references potential medical applications, including BPC-157 for ulcerative colitis treatment.
Kennedy discussed this policy shift during a podcast appearance with Joe Rogan, where both men shared personal peptide experiences and claimed positive results.
“I’m a big fan of peptides,” Kennedy stated to Rogan. “I’ve used them myself and with really good effect on a couple of injuries.”
Kennedy characterized the Biden administration’s peptide restrictions as an “illegal” action that improperly classified these substances.
Peptides function as fundamental components that form larger proteins. Within human physiology, peptides activate hormones essential for growth, metabolic processes and tissue repair.
Recent years have brought peptides into mainstream awareness through successful GLP-1 medications, which received FDA approval for obesity and diabetes management. Additional approved peptide treatments include insulin for diabetic patients and hormone-based therapies for various medical conditions.
However, many peptides marketed online have never received official approval, making their drug marketing technically prohibited. International sports organizations have banned several peptides, including BPC-157 and TB-500, as performance-enhancing substances.
Despite regulatory concerns, these treatments have established a strong presence in the expanding wellness and alternative medicine marketplace.
Specialized wellness facilities offer in-clinic injections or intravenous treatments, sometimes charging monthly membership fees reaching thousands of dollars.
Simultaneously, some dietary supplement manufacturers have started incorporating peptides into capsules, protein powders and gummy products. During a recent FDA session, industry representatives advocated for broadening federal supplement definitions to accommodate newer ingredients like peptides.
When federal regulators restricted injectable peptides in 2023, they cited safety concerns including cancer risks and potential liver, kidney and heart complications. Pharmacies violating these restrictions face financial penalties, legal consequences or possible state license revocation.
These measures prompted opposition from wellness business owners, compounding pharmacies and their political supporters.
Last year, multiple Congressional representatives, including Republican Senator Tommy Tuberville from Alabama, contacted Kennedy requesting the removal of peptide production limitations.
The compounding industry has maintained that FDA restrictions have encouraged an underground market for imported chemicals from China and other nations, which operate outside U.S. pharmaceutical standards.
Social media platforms like TikTok feature international suppliers offering numerous peptide options for as low as $5 per container. These products typically display “for research use only” labels. Legal experts explain this language attempts to circumvent FDA oversight, since the agency doesn’t regulate chemicals not intended for human consumption.
Kennedy has supported the compounding industry’s position regarding unintended regulatory consequences.
“With the gray market you have no idea if you’re getting a good product,” Kennedy explained to Rogan. “And a lot of this stuff that we’ve looked at is just very, very substandard.”
